title: Tocolytic therapy for acute preterm labor.
abstract: The pathophysiology leading to preterm labor is not well understood and often multifactorial; initiating factors include intrauterine infection, inflammation, ischemia, overdistension, and hemorrhage. Given these different potential causes, directing therapy for preterm labor has been difficult and suboptimal. To date, no single drug has been identified as successful in treating all of the underlying mechanisms leading to preterm labor. In addition, the methodology of many of the tocolytic studies is limited by lack of sufficient patient numbers, lack of comparison with a placebo, and inconsistent use of glucocorticoids. The limitations in these individual studies make it difficult to evaluate the efficacy of a single tocolytic by meta-analysis. Despite these limitations, the goals for tocolysis for preterm labor are clear: To complete a course of glucocorticoids and secure the appropriate level of neonatal care for the fetus in the event of preterm delivery. The literature demonstrates that many tocolytic agents inhibit uterine contractility. The decision as to which tocolytic agent should be used as first-line therapy for a patient is based on multiple factors, including gestational age, the patient’s medical history, common and severe side effects, and a patient’s response to therapy. In a patient at less than 32 weeks gestation, indomethacin may be a reasonable first choice based on its efficacy, ease of administration, and minimal side effects. Concurrent administration of magnesium for neuroprotection may be given. At 32 to 34 weeks, nifedipine may be a reasonable first choice because it does not carry the fetal risks of indomethacin at these later gestational ages, is easy to administer, and has limited side effects relative to beta-mimetics. In an effort to review a commonly faced obstetrical complication, this article has provided a summary of the most commonly used tocolytics, their mechanisms of action, side effects, and clinical data regarding their efficacy.
authors.affiliation: Division of Maternal-Fetal Medicine, University of Alabama, Birmingham, 619 19th Street South 176F 10270C, Birmingham, AL 35249-7333, USA. adi.abramovici@obgyn.uab.edu
authors.forename: Adi
authors.initials: A
authors.lastname: Abramovici
authors.forename: Jessica
authors.initials: J
authors.lastname: Cantu
authors.forename: Sheri M
authors.initials: SM
authors.lastname: Jenkins
mesh_terms: D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005865:Gestational Age; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D017616:Magnesium Compounds / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D011247:Pregnancy; D018566:Pregnancy, High-Risk; D015145:Tocolysis / Q000379:methods*; D015149:Tocolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology
chemical_list: D002121:Calcium Channel Blockers; D017616:Magnesium Compounds; D015149:Tocolytic Agents; D009543:Nifedipine; D007213:Indomethacin